Reßing et al. executed a medicinalchemistry campaign to rationallydesign a novel class of peptoid-based histone deacetylase inhibitors(HDACi).59 Eleven peptide-based HDACi weresynthesized and screened over CHP-134, IMR-32, SK-N-AS, and NB-1 (neuroblastoma)and G55T2 (glioblastoma) cell lines, where 57 was foundto be most potent in the series, with the IC50 values shownin Figure 14C. Additionally,the selectivity profile of all compounds was studied for HDAC1 andHDAC6, where 57 was found to be non-selective againstHDAC1 and HDAC6. This evidence concerns the gene HDAC6 and glioblastoma.